Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01280695 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Metabolic Solutions Development Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 14
- Study locations
NCT01280695: Completed Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Metabolic Solutions Development Company.
NCT01280695 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Metabolic Solutions Development Company. The registered enrollment target is 129 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01280695, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Metabolic Solutions Development Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
Primary Outcome
To characterize the reduction in fasting plasma glucose in response to three different doses of MSDC-0602 Tablets as compared to placebo following once-daily dosing for 28 consecutive days in patients with Type 2 diabetes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG MSDC-0602 100 mg
- DRUG MSDC-0602 250 mg
Study Locations (14)
Florida
- - Bradenton
- - Hialeah
- - Pembroke Pines
California
- - Chula Vista
- - Los Angeles
Texas
- - Austin
- - San Antonio
Arizona
- - Goodyear
Illinois
- - Chicago
Montana
- - Butte
North Carolina
- - Greensboro
Ohio
- - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
What the finished NCT01280695 record still lists
NCT01280695 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01280695 lists 14 locations in 10 states (Florida, California, Texas).
Frequently Asked Questions
What is clinical trial NCT01280695 about?
NCT01280695 is a clinical study titled "A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients". The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
What is the current status of trial NCT01280695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2011-02. Estimated completion is 2011-06.
What conditions does trial NCT01280695 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01280695?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), MSDC-0602 100 mg (DRUG), MSDC-0602 250 mg (DRUG).
Who is sponsoring clinical trial NCT01280695?
This trial is sponsored by Metabolic Solutions Development Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01280695 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Illinois, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01280695's enrollment target sits among peer trials
129 185th of 348 higher than 164 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia